MBXMBX Biosciences, Inc.
$53.26+433% 1Y
$53.26
$13.2252 weeks$70.67
MBX as reported
- Net income
- −$104M
Net income · +35% year on year · trailing twelve months to Q2 2026
- Free cash flow
- −$85M
Free cash flow · +19% year on year · trailing twelve months to Q2 2026
- EPS
- −$2.36
EPS · −143% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net income | −$104M | +35% | Q2 2026 |
| EPS | −$2.36 | −143% | Q2 2026 |
| ROE | −22% | n/a | Q2 2026 |
| ROA | −21% | n/a | Q2 2026 |
| Free cash flow | −$85M | +19% | Q2 2026 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
MBX Biosciences, Inc. (MBX) · Net incomeNet incomeMBX Biosciences, Inc. (MBX)
Biotechnology
The closest names by size in the same industry